676134-13-7

Basic information

• Product Name: tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate
• Synonyms: tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate
• CAS NO: 676134-13-7
• Molecular Weight: 518.644
• Mol File: 676134-13-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate(676134-13-7)
• EPA Substance Registry System: tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate(676134-13-7)

Safety Data

• Hazardous Substances Data: 676134-13-7(Hazardous Substances Data)

Upstream product

• 388071-27-0 tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate 
• 676134-09-1 (4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-ylamine 
• 116212-82-9 ZnCl(neopentyl) 
• 676133-70-3 tert-butyl (1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-iodo-3,4-dihydro-2H-chromen-4-yl]amino}propylcarbamate 
• 1356847-46-5 C₁₄H₁₉N₃O 
• 120523-16-2 (R)-4-chromanol 
• 676133-67-8 (R)-6-iodochroman-4-ol 
• 13132-23-5 2,2-dimethylpropylmagnesium chloride 

Downstream Products

• 676134-02-4 N-((1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(4S)-6-neopentyl-3,4-dihydro-2H-chromen-4-yl]amino}propyl)acetamide 

Relevant articles and documents

Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: Prime side chromane-containing inhibitors

The structure activity relationship of the prime region of conformationally restricted hydroxyethylamine (HEA) BACE inhibitors is described. Variation of the P1′ region provided selectivity over Cat-D with a series of 2,2-dioxo-isothiochromanes and optimi

METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.